ALLMedicine™ Antinuclear Antibody Center

Jun 30th, 2022 - Clinical and Autoantibody Associations in Antinuclear Antibody-Positive Systemic Sclerosis Lacking Prototypic Autoantibodies.|2022|Kruzer K,Goncalves Marangoni R,Heckler I,Elhage A,Varga J,|

Jun 28th, 2022 - To the Editor: Tumor necrosis factor α (TNF-α) inhibitor–induced lupuslike syndrome (TAILS) is a newly described entity that refers to the onset of subacute cutaneous lupus erythematosus (SCLE) during drug therapy with TNF-α antagonists. The condi.

Jun 28th, 2022 - The study was to investigate the clinical characteristics and significance of antinuclear antibody (ANA) cytoplasmic patterns in ANCA-associated vasculitis (AAV) from Southwest China.A retrospective study including 232 AAV patients from Peoples Ho...

Jun 23rd, 2022 - This patient presented with a 1-year history of violaceous-brown, coalescing reticulated macules on his face, with no similar lesions in other body areas. Laboratory findings were normal and antinuclear antibody test was negative. Histopathologica...

Jun 23rd, 2022 - The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from ...

Jun 23rd, 2022 - The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from ...

May 26th, 2022 - Study KD025-206 was a phase 2, open-label, dose-finding, safety, tolerability, activity, and PK study of KD025 in subjects with psoriasis who had failed at least 1 line of systemic therapy or phototherapy. Subjects received KD025 PO for 12 weeks. ...

May 11th, 2022 - This is a prospective, open-label, nonrandomized, multicenter clinical trial aiming at comparing the efficacy and safety of combined use of eltrombopag with low-dose rituximab vs. the best available therapy（BAT）in adult immune thrombocytopenia (...

Jan 4th, 2022 - Patients with a proven history or current exposure will have 4 EDTA tubes drawn, approximately 24mL of fresh whole blood for efferocytosis assessment and : 2 x 6mL serum tubes for the assessment of Antinuclear Antibody (ANA) positivity, serum high...

Aug 6th, 2021 - This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult ITP patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag t...

Jun 28th, 2022 - To the Editor: Tumor necrosis factor α (TNF-α) inhibitor–induced lupuslike syndrome (TAILS) is a newly described entity that refers to the onset of subacute cutaneous lupus erythematosus (SCLE) during drug therapy with TNF-α antagonists. The condi.

Jun 17th, 2022 - The Food and Drug Administration has approved a new diagnostic blood test to detect monospecific Ribosomal P antibodies to support a diagnosis of systemic lupus erythematosus (SLE), particularly for people who are antinuclear antibody-negative, ac...

May 25th, 2022 - Case Report A 60-year-old man presented with eroded areas in the mouth and blistering eruptions on the scalp, face, trunk, arms, and legs. He initially presented to an outside hospital 4 years prior and was treated with oral prednisone 50 mg daily.

Mar 16th, 2022 - What could be the first oral medication specific for systemic lupus erythematosus (SLE) was more effective than placebo in a randomized phase II trial, though the results were something less than a home run. With 288 patients assigned to three dos...

Mar 9th, 2022 - Although psoriatic arthritis is not the only disease associated with dactylitis — other culprits are sarcoidosis, septic arthritis, tuberculosis, and gout — dactylitis is one of the characteristic symptoms of psoriatic arthritis. Dactylitis is see.